Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it acquired from Verve Therapeutics, with the candidate now showing strong and consistent cholesterol ...

Though the results show competitive efficacy and tolerability, they may leave some observers slightly underwhelmed based on ...

Biogen axed an Ionis-partnered antisense oligonucleotide that targets LRRK2 last year. Other biotechs continue to work on the ...

One day in early May, web-based prediction market platform Kalshi listed two contracts tied to Compass Pathways’ psilocybin ...

It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform. But that’s a lifetime in ...

Infex Therapeutics is pushing ahead with the development of a non-cystic fibrosis bronchiectasis (NCFB) drug candidate after ...

OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate and Keytruda in ovarian cancer, linking ...

Cancer immunotherapy company Liminatus Pharma has agreed to pay out shares worth $320 million to buy CAR-T biotech InnocsAI. | Cancer immunotherapy company Liminatus Pharma has agreed to pay out ...

Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs.

Recorded last week at Fierce Biotech Week in Boston, this episode of “The Top Line” features a conversation with Kristen ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Fosun Pharma has paid $60 million for an option on AriBio’s late-phase Alzheimer’s disease program, securing the chance to ...